Medical/Pharmaceuticals
AWAK TECHNOLOGIES RAISES US$20+ MILLION, READYING ITS WEARABLE DIALYSIS DEVICE FOR US-BASED PIVOTAL TRIAL
* AWAK closes one of the largest MedTech fundraise in 2023 in Southeast Asia * The Series B round was co-led by new investor Lion X Ventures and long-term investor Vickers Venture Partners, along with other new and existing investors * AWAK's ultra-portable peritoneal dialysis system enables ...
2023-09-13 21:27
2043
S-Patch Ex, Wearable ECG Patch, Cleared by US FDA
* Lightest weighing ECG patch in the market designed for comfort and ease of use * Embedded with Samsung's Next-Generation bio-processor proven to capture world's most accurate ECG waveforms SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- Wellysis, a spin-off company from Samsung SDS, has ...
2023-09-13 21:00
1633
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In May 2023, the U.S. Food and Drug Administration (FDA) cleared Insilico's I...
2023-09-13 20:29
1599
Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the clinical trial of oral APL-12...
2023-09-13 19:09
1313
J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI
SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- J INTS BIO announced that Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' was presented at the 2023 IASLC World Conference on Lung Cancer held inSingapore from 9th to 12th September, during the official session...
2023-09-13 15:58
1434
Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China
SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Recently, BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "Bioray") announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection (trade name: Anruixi®), indicated for the treatment of CD20...
2023-09-13 14:24
1243
Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of Over 50% and Reduced Pain by 4.7
- CBL-0201DD Phase 2 study met the primary and all secondary endpoints. - 64.5% of painful lipomas showed complete clearance or dimensions reduction of more than 50% after CBL-514 treatments. - 54.8% of painful lipomas showed complete clearance or dimension reduction of more th...
2023-09-13 13:42
1164
AIRS Medical Inc. receives MDSAP Certification, Paving the Way for Global Expansion
SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- AIRS Medical Inc., an AI-powered healthcare solution provider headquartered in Korea announces the attainment of MDSAP (Medical Device Single Audit Program) certification. This milestone achievement underscores AIRS Medical's commitment to qualit...
2023-09-13 12:44
1262
Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets
SINGAPORE, Sept. 13, 2023 /PRNewswire/ -- Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 ...
2023-09-13 10:30
2174
Maxigen Biotech Inc. Wins 2023 Asia's Leading SMEs Award for Innovative Sustainability
KUALA LUMPUR, Malaysia, Sept. 13, 2023 /PRNewswire/ -- Maxigen Biotech
Inc.(MBI), a pioneering biotech company headquartered inTaiwan, has been
honored with the prestigious 2023 Asia's Leading SMEs Award by ACES
underscoring its commitment to innovation and sustainable operations.
2023-09-13 09:30
1782
GemPharmatech's Board Appoints Brandy Wilkinson, Ph.D. as its New Chief Executive Officer of GemPharmatech LLC.
SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- GemPharmatech LLC., a leading
contract research organization, announced today that its Board of Directors has
appointed Dr.Brandy Wilkinson as the Chief Executive Officer of its subsidiary
inthe United States, effective September 12, 2023.
2023-09-13 00:00
1309
Frost & Sullivan Recognizes Suki AI with the 2023 North American Technology Leadership Award
Suki's innovative AI Assistant brings the power of Generative AI to health systems and delivers strong ROI SAN ANTONIO, Sept. 12, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the healthcare voice assistant industry and, based on its findings, recognizesSuki AI with the 2023 North Am...
2023-09-12 22:00
1575
TMRW Life Sciences Receives CE Mark for the CryoRobot Select, its Next-Generation Automated Platform to Safely Manage and Store Frozen Eggs and Embryos
TMRW's Cutting-Edge Technology is Raising the Standard of Care in Global Fertility NEW YORK, Sept. 12, 2023 /PRNewswire/ -- TMRW Life Sciences, a fertility technology company automating the IVF lab, today announced that it has received a CE Mark for the CryoRobot Select (CRS). The European desig...
2023-09-12 21:01
1515
Standigm's "Green Ribbon Campaign" to support Mitochondria Disease Awareness Week
SEOUL, South Korea, Sept. 12, 2023 /PRNewswire/ -- On September 5th, 2023 Standigm, a company using artificial intelligence (AI) technology for drug discovery and development launched, the "Green Ribbon Campaign," event to support the upcoming Mitochondrial Disease Awareness Week scheduled for Se...
2023-09-12 21:00
1247
CSafe Expands Executive Team with Chief Financial Officer
Seasoned financial leader, Anthony Pishotti, joins CSafe executive team to further drive the company's portfolio and geographic growth. MONROE, Ohio, Sept. 12, 2023 /PRNewswire/ -- CSafe, the largest active and passive temperature-controlled shipping solutions provider for the biopharmaceutical ...
2023-09-12 20:59
1819
Datasea Announces Pricing of $2.0 Million Underwritten Public Offering
BEIJING, Sept. 12, 2023 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada incorporated digital technology corporation engaged in converging and innovative business segments for intelligent acoustics and 5G messaging technology inChina, today announced the pricing ...
2023-09-12 20:30
4099
Pierre Fabre Laboratories Acquires Vertical Bio and its Innovative Targeted Therapy Candidate for Patients Suffering From Non-Small Cell Lung Cancer With MET Alteration
CASTRES, France and BASEL, Switzerland, Sept. 12, 2023 /PRNewswire/ --
Pierre Fabre Laboratories
2023-09-12 20:00
1263
New South Wales Government (NSW) Partner, Myeloid Therapeutics, Initiates Patient Dosing with MT-302 in Phase 1 Study at Clinical Site in Australia
NSW and Myeloid entered into a partnership in February 2023 to launch state-of-the-art GMP manufacturing RNA facility CAMBRIDGE, Mass., Sept. 12, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage oncology company, has dosed the first patient with MT-302 in a Phase 1 s...
2023-09-12 20:00
970
Metabolon Launches New Biological Stress Discovery Panel to Aid Detection of Inflammation and Biological Stress Biomarkers
Metabolon's new Biological Stress Discovery Panel supports inflammation, immune function, and stress research with advanced analytics MORRISVILLE, N.C., Sept. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of research, di...
2023-09-12 19:57
1035
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA
* HANSIZHUANG's coverage footprint includes 22 emerging market countries acrossSoutheast Asia and MENA – * KGbio to develop and commercialise HANSIZHUANG in 12 MENA countries; Henlius to receiveUS$7 million upfront payment plus royalties and up to US$8 million in regulatory milestone payments...
2023-09-12 19:24
1232
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 256 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 251 media titles]
2024-04-30 15:13Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2938
